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Review Article
Introduction
Type 1 diabetes mellitus (T1DM) affects approximately 
1.25 million American adults and children and accounts for 
5% to 10% of all patients with diabetes.1 Insulin therapy is 
the cornerstone treatment of T1DM and is successful in pre-
venting diabetic ketoacidosis, an immediate and potentially 
fatal consequence of insulin deficiency. However, adequate 
glucose control to prevent long-term complications, such as 
diabetic nephropathy, peripheral neuropathy, and retinopa-
thy, is often difficult to attain with insulin alone. This was 
seen in a study spanning over a total of 30 years, in which 
hemoglobin A
1C
 (A1C) averaged 7.2% in patients receiving 
intensive insulin treatment and remained above goal at 10 
years (7.9%) and 30 years (8.0%) after study initiation.2 
Intensive insulin therapy that does not achieve A1C goals 
could place the patient at increased risk for long-term 
complications.3 Owing to an increased prevalence of obe-
sity in T1DM and its association with insulin resistance, 
innovative approaches to glucose control have become 
necessary.4 An explosion of novel antidiabetic treatments 
have recently come into the market, but only pramlintide 
(Symlin), an analog of amylin, has gained Food and Drug 
Administration (FDA) approval for T1DM. This has begged 
the question as to which, if any, of these new agents could 
have utility in T1DM? Glucagon-like peptide 1 (GLP-1) has 
been shown to have insulinotropic and glucagonostatic 
properties, making GLP-1 agonists an ideal area for investi-
gation in T1DM.5,6
Data Sources
To obtain relevant literature, a search using MEDLINE, 
EMBASE, and the Cochrane Database was performed, 
through March 2016, using the key terms type 1 diabetes 
mellitus together with GLP-1 agonists, incretin, liraglutide, 
exenatide, albiglutide, and dulaglutide, respectively. 
References of all articles were reviewed for relevant cita-
tions. Studies eligible for inclusion in this review were 
English-language, human clinical trials of GLP-1 agonists 
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Abstract
Objective: To review the use of GLP-1 agonists in patients with type 1 diabetes mellitus (T1DM). Data Sources: A 
search using the MEDLINE database, EMBASE, and Cochrane Database was performed through March 2016 using the 
search terms glucagon-like peptide 1 (GLP-1) agonists, incretin, liraglutide, exenatide, albiglutide, dulaglutide, type 1 diabetes 
mellitus. Study Selection and Data Extraction: All English-language trials that examined glycemic end points using GLP-
1 agonists in humans with T1DM were included. Data Synthesis: A total of 9 clinical trials examining the use of GLP-1 
agonists in T1DM were identified. On average, hemoglobin A
1C
 (A1C) was lower than baseline, with a maximal lowering 
of 0.6%. This effect was not significant when tested against a control group, with a relative decrease in A1C of 0.1% to 
0.2%. In all trials examined, reported hypoglycemia was low, demonstrating no difference when compared with insulin 
monotherapy. Weight loss was seen in all trials, with a maximum weight loss of 6.4 kg over 24 weeks. Gastrointestinal 
adverse effects are potentially limiting, with a significant number of patients in trials reporting nausea. Conclusion: The 
use of GLP-1 agonists should be considered in T1DM patients who are overweight or obese and not at glycemic goals 
despite aggressive insulin therapy; however, tolerability of these agents is a potential concern. Liraglutide has the strongest 
evidence for use and would be the agent of choice for use in overweight or obese adult patients with uncontrolled T1DM.
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that reported glycemic outcomes. Glycemic outcomes are 
defined as A1C or plasma glucose measurements. Studies in 
patients who had undergone islet transplantation or that uti-
lized either single or intermittent dosing were excluded 
from this review. A total of 9 trials met inclusion criteria. 
Details regarding study inclusion are reported in Figure 1.
Pathophysiology
T1DM results from autoimmune destruction of the pancre-
atic β-cells, causing insulin deficiency. As a consequence, 
patients require exogenous insulin for treatment. Although 
the rate and extent of destruction of β-cells is highly vari-
able, measurable residual function remains in nearly 100% 
of newly diagnosed patients after the first year.5 Remaining 
insulin secretion can be measured indirectly through obtain-
ing serum concentrations of C-peptide, which is cleaved 
from proinsulin during endogenous insulin production in 
equimolar amounts to insulin. The hallmark of diagnosis of 
T1DM is the presence of autoantibodies to at least 1 known 
autoimmune marker, though this can occur before any clini-
cal signs or symptoms of diabetes are present.7 In addition 
to insulin deficiency, several other underlying metabolic 
disturbances have been implicated in T1DM, including 
excess production of glucagon in the presence of hypergly-
cemia leading to inappropriate gluconeogenesis, increased 
levels of free fatty acids, rapid gastric emptying, and 
decreased sensation of satiety.5,8 Provision of exogenous 
insulin fails to address these other manifestations of endo-
crine dysfunction, leading to potential targets of therapy for 
T1DM.
Gaps in Treatment
Currently, there are only 2 treatment modalities approved 
for T1DM in the United States: insulin and pramlintide. 
Treatment with exogenous insulin has been the mainstay of 
management of T1DM patients for decades, and a plethora 
of insulin analogs are currently available; however, inten-
sive insulin therapy causes hypoglycemic episodes (62 inci-
dents/100 patient-years) and weight gain of approximately 
4.6 kg over a period of 10 years.9 In addition, many patients 
fail to reach A1C goals despite aggressive treatment.2 
Pramlintide, an analog of amylin, has many actions similar 
to GLP-1 agonists, including delayed gastric emptying, 
decreased glucagon secretion, and increased satiety. In clin-
ical trials, use of pramlintide 3 or 4 times daily in T1DM 
patients led to reductions in A1C of 0.29% and 0.34%, 
respectively, over 52 weeks.10 Unfortunately, it has been 
associated with hypoglycemia in T1DM, a cause for 
concern.10 Metformin has been studied in T1DM with 
mixed results on changes in insulin sensitivity and without 
statistically significant changes in A1C.11,12 Currently, 
dipeptidyl peptidase-4 (DPP4) and sodium-glucose cotrans-
porter 2 (SGLT-2) inhibitors are also under investigation for 
use in T1DM.13-16 Over the past decade, GLP-1 agonists 
Figure 1. Flowchart of study inclusion.
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have been the most rigorously studied noninsulin agents for 
T1DM. Several proof-of-concept studies showed reduc-
tions in postprandial hyperglycemia and serum glucose area 
under the curve (AUC) following single doses of up to 3 
days of therapy.17,18 Below, we discuss the role of GLP-1 in 
T1DM, evidence for specific GLP-1 agonists in T1DM, and 
clinical implications in depth.
GLP-1 Agonists in T1DM
GLP-1 is an endogenous hormone that regulates secretion 
of both insulin and glucagon in response to meals. In the 
presence of postprandial hyperglycemia, GLP-1 stimulates 
insulin release from β cells and suppresses glucagon release 
from pancreatic α cells. It is hypothesized that a paradoxical 
increase in glucagon in T1DM could be responsible for the 
erratic blood glucose control often seen in patients appro-
priately treated with insulin therapy; thus, GLP-1 agonists 
could have utility in T1DM.5,6 Because GLP-1 activity is a 
glucose-dependent mechanism, risk for hypoglycemia is 
low.19 Additionally, GLP-1 slows gastric emptying through 
effects on the autonomic nervous system and acts centrally 
to increase satiety. The resultant decrease in oral intake is 
thought to be the mechanism that induces weight loss.20 
This effect is observed regardless of baseline weight and 
has led to FDA approval of 1 agent, liraglutide, as an adjunct 
to diet and exercise for weight loss in obese, nondiabetic 
patients.5,19,20 These agents are available as subcutaneous 
injections with varying dosing intervals.
Evidence for the use of GLP-1 agonists in T1DM is 
limited and varies based on agent. Various proof-of-con-
cept studies for both exenatide and liraglutide demon-
strated a decrease in plasma glucose when added to insulin 
therapy.17,18,21,22 This led to additional clinical trials for 
GLP-1 agonists in T1DM, evaluating extended GLP-1 use 
and corresponding glycemic outcomes. Each will be dis-
cussed independently, including relevant published stud-
ies and those currently in process.
Exenatide
Exenatide was first approved for use in the United States as 
a twice-daily, immediate release subcutaneous injection. 
Several years later, an extended release formulation was 
additionally approved. Drug levels of the twice daily prepa-
ration are detectable for only 6 to 7 hours after dosing, 
which results in intermittent stimulation of the GLP-1 
receptor.6 The once-weekly formulation allows for continu-
ous stimulation of the GLP-1 receptor and has been noted to 
have significantly increased gastric emptying as compared 
with twice-daily dosing.6 Use of exenatide to augment insu-
lin therapy in T1DM patients has been evaluated since 
2009.20 The majority of studies in T1DM utilize the imme-
diate release formulation. Although data are conflicting and 
limited, these data have been used to shape GLP-1 use in 
T1DM. A review of published data reveals 3 studies utiliz-
ing exenatide beyond a single dose, all in adult patients 
(Table 1).16,20,23 Clinical trials range from 3 to 18 months, 
limiting available long-term outcomes; however, the clini-
cal findings are useful to consider in T1DM patients.
The first clinical trial to explore GLP-1 agonist use in 
T1DM patients simultaneously evaluated the impact of an 
immunomodulator (daclizumab) and exenatide on β-cell 
function and glycemic control.20 Rother et al20 executed a 
4-arm crossover clinical trial with insulin, exenatide, and 
daclizumab in various combinations: insulin monotherapy, 
insulin + exenatide, insulin + exenatide + daclizumab, or 
insulin + daclizumab. Participants underwent an optimiza-
tion period for 2 to 4 months to achieve improved glycemic 
control. The optimization period was followed by a 4-month 
run-in phase, which prohibited any major changes to their 
insulin regimen and diabetes management. Patients were 
randomized to group A, insulin or insulin + exenatide, or 
group B, exenatide + daclizumab + insulin or daclizumab + 
insulin. After 6 months of treatment, patients in each group 
switched treatment arms to alter receipt of exenatide. The 
dose and frequency were titrated from exenatide 2.5 µg 
twice daily to 10 µg 4 times daily; however, no data are 
provided about the number of patients reaching the 40-µg 
daily exenatide doses. With each exenatide titration, the 
authors noted corresponding reductions in insulin doses. An 
independent examination of exenatide patients demon-
strated no effect on C-peptide secretion or fasting glucagon, 
likely because of an average duration of T1DM of 21 years. 
Interestingly, exenatide did not alter A1C during the study 
period but did improve weight loss without dropout because 
of gastrointestinal (GI) adverse drug reactions (ADRs).20 A 
subgroup analysis of this study also evaluated insulin sensi-
tivity in 13 exenatide patients enrolled within the larger 
trial.24 In these patients, exenatide was associated with 
improved insulin sensitivity, specifically pertaining to post-
prandial blood glucose control.24
Insulin augmentation with exenatide has also been com-
pared with augmentation with sitagliptin in adult patients 
newly diagnosed with T1DM within the previous month.16 
Patients were randomized to 1 of 3 treatment arms: insulin 
monotherapy, insulin + exenatide, or insulin + sitagliptin. 
All 3 treatment arms showed improvement in A1C and 
decreased insulin requirements at 1 year. Similar to previous 
studies, treatment with exenatide had no impact on C-peptide 
secretion. Two patients reported nausea with exenatide; 
however, neither participant withdrew from the study.16
Finally, a recent retrospective analysis was completed in 
patients receiving weekly extended-release exenatide.23 
Patients served as their own controls, and data was collected 
at baseline and 3 months after beginning treatment. 
Statistically significant improvements in A1C, body mass 
index (BMI), and insulin requirement were seen at 3 months.23
 at BUTLER UNIV on June 6, 2016aop.sagepub.comDownloaded from 
4 
T
ab
le
 1
. 
Su
m
m
ar
y 
of
 S
tu
di
es
 o
f E
xe
na
tid
e 
in
 P
at
ie
nt
s 
W
ith
 T
1D
M
.a
A
ut
ho
r(
s)
St
ud
y 
D
es
ig
n 
an
d 
In
cl
us
io
n 
C
ri
te
ri
a
Ba
se
lin
e 
C
ha
ra
ct
er
is
tic
s
N
um
be
r 
of
 
Pa
tie
nt
s
St
ud
y 
D
ur
at
io
n
C
ha
ng
e 
in
 
A
1C
C
ha
ng
e 
in
 
Pl
as
m
a 
G
lu
co
se
C
ha
ng
e 
in
 In
su
lin
 
D
os
e
C
ha
ng
e 
in
 
W
ei
gh
t 
or
 B
M
I
C
om
m
en
ts
R
ot
he
r 
et
 a
l20
,b
••
Pr
os
pe
ct
iv
e
••
R
an
do
m
iz
ed
••
O
pe
n-
la
be
l c
ro
ss
ov
er
••
Ex
en
at
id
e 
vs
 
ex
en
at
id
e/
da
cl
iz
um
ab
 
vs
 d
ac
liz
um
ab
 v
s 
in
su
lin
 m
on
ot
he
ra
py
In
cl
us
io
n 
cr
ite
ri
a
••
18
-6
0 
Y
ea
rs
 o
f a
ge
••
BM
I >
25
 k
g/
m
2
••
D
ia
gn
os
is
 fo
r 
≥5
 
ye
ar
s
••
A
ge
 3
9 
ye
ar
s
••
D
ur
at
io
n 
of
 
di
se
as
e 
21
.3
 y
ea
rs
••
A
1C
 7
.3
%
 ±
 1
.1
%
••
BM
I 2
5.
9 
kg
/m
2
20
18
 M
on
th
s
−
0.
13
%
 w
ith
 
ex
en
at
id
e
N
R
−
0.
07
 IU
/k
g/
dc
 
fr
om
 b
as
el
in
e
−
4.
1 
kg
c  f
ro
m
 
ba
se
lin
e
••
Ex
en
at
id
e 
2.
5 
µg
 
tw
ic
e 
da
ily
 t
itr
at
ed
 t
o 
10
 µ
g 
4 
tim
es
 d
ai
ly
, a
s 
to
le
ra
te
d
••
D
ac
liz
um
ab
 2
 m
g/
kg
 
IV
 o
nc
e 
m
on
th
ly
••
N
o 
G
I A
D
R
s 
re
po
rt
ed
••
H
yp
og
ly
ce
m
ia
 s
im
ila
r 
be
tw
ee
n 
ex
en
at
id
e 
gr
ou
ps
 (
1.
21
 e
pi
so
de
s 
pe
r 
w
ee
k 
on
 
ex
en
at
id
e)
H
ar
i K
um
ar
 e
t 
al
16
,b
••
Pr
os
pe
ct
iv
e
••
R
an
do
m
iz
ed
••
O
pe
n 
la
be
l
••
Ex
en
at
id
e 
vs
 
si
ta
gl
ip
tin
 v
s 
in
su
lin
 
m
on
ot
he
ra
py
In
cl
us
io
n 
cr
ite
ri
a
••
>
18
 Y
ea
rs
 o
f a
ge
••
C
-p
ep
tid
e 
>
0.
1 
ng
/
m
L
••
A
ge
 2
8 
ye
ar
s
••
D
ur
at
io
n 
of
 
di
se
as
e 
1.
1 
m
on
th
s
••
A
1C
 9
.7
%
 ±
 0
.8
%
••
BM
I 2
1.
5 
kg
/m
2
18
12
 M
on
th
s
−
0.
3%
 
di
ffe
re
nc
e 
w
ith
 
ex
en
at
id
e
N
R
••
−
24
.1
 IU
/d
••
−
0.
4 
IU
/
kg
/d
−
4.
5 
kg
 fr
om
 
ba
se
lin
e
••
Ex
en
at
id
e 
5 
µg
 t
w
ic
e 
da
ily
 t
itr
at
ed
 t
o 
10
 
µg
 t
w
ic
e 
da
ily
, a
s 
to
le
ra
te
d
••
N
au
se
a 
in
 1
1%
 (
n 
=
 2
)
••
H
yp
og
ly
ce
m
ia
 s
im
ila
r 
be
tw
ee
n 
gr
ou
ps
 (
3 
ep
is
od
es
 r
ep
or
te
d 
w
ith
 e
xe
na
tid
e)
T
ra
in
a 
et
 a
l23
••
R
et
ro
sp
ec
tiv
e
••
N
o 
co
m
pa
ra
to
r
In
cl
us
io
n 
cr
ite
ri
a
••
>
18
 Y
ea
rs
 o
f a
ge
••
D
ia
gn
os
is
 fo
r 
>
6 
m
on
th
s
••
A
ge
 5
3 
ye
ar
s
••
D
ur
at
io
n 
of
 
di
se
as
e 
39
 y
ea
rs
••
A
1C
 7
.7
0%
 ±
 
0.
95
%
••
BM
I 2
9.
8 
kg
/m
2
11
3 
M
on
th
s
−
0.
6%
c  f
ro
m
 
ba
se
lin
e
−
12
.3
 m
g/
dL
 
fr
om
 b
as
el
in
e
••
Bo
lu
s:
 −
7.
8 
IU
/d
c  f
ro
m
 
ba
se
lin
e
••
Ba
sa
l: 
−
3.
3 
IU
/d
 fr
om
 
ba
se
lin
e
−
1.
7 
kg
/m
2c
 
fr
om
 b
as
el
in
e
••
Ex
en
at
id
e 
do
se
 n
ot
 
pr
ov
id
ed
••
H
yp
og
ly
ce
m
ia
 e
ve
nt
s 
in
cr
ea
se
d 
by
 3
.7
 
ep
is
od
es
 in
 t
he
 fi
rs
t 
28
 d
ay
s
A
bb
re
vi
at
io
ns
: A
1C
, h
em
og
lo
bi
n 
A
1C
; A
D
R
, a
dv
er
se
 d
ru
g 
re
ac
tio
ns
; B
M
I, 
bo
dy
 m
as
s 
in
de
x;
 G
I, 
ga
st
ro
in
te
st
in
al
; I
U
, i
nt
er
na
tio
na
l u
ni
ts
; I
V
, i
nt
ra
ve
no
us
; N
R
, n
ot
 r
ep
or
te
d;
 T
1D
M
, t
yp
e 
I d
ia
be
te
s 
m
el
lit
us
.
a A
ll 
st
ud
y 
gr
ou
ps
 w
er
e 
on
 in
su
lin
 t
he
ra
py
; d
at
a 
ar
e 
re
po
rt
ed
 a
s 
m
ea
n 
va
lu
es
 fo
r 
th
e 
ov
er
al
l s
tu
dy
.
b R
es
ul
ts
 li
st
ed
 a
re
 in
su
lin
 +
 e
xe
na
tid
e 
re
la
tiv
e 
to
 in
su
lin
 t
he
ra
py
 a
lo
ne
 (
pl
ac
eb
o)
.
c S
ta
tis
tic
al
ly
 s
ig
ni
fic
an
t 
(P
 <
 0
.0
5)
.
 at BUTLER UNIV on June 6, 2016aop.sagepub.comDownloaded from 
Janzen et al 5
To date, exenatide has safety and efficacy data for up to 
18 months in T1DM, the longest of any GLP-1 agonist.20 
Supplementing insulin therapy with exenatide led to low-
ered total daily dose (TDD) of insulin, up to 24 IU/d, and 
delayed gastric emptying, with corresponding weight loss. 
The sample size was limited, with no more than 20 patients 
included in any single study. Comparator groups were not 
consistent and included other antidiabetic drugs (sita-
gliptin) and immunomodulator therapy (daclizumab).16,20,23 
Study design was also inconsistent across studies, with 1 
study including a run-in phase that was not clearly 
described.20 Prospective research has been limited to 
immediate release formulations of exenatide; however, a 
recent retrospective analysis shows promise for extended-
release formulations.23 Prospective investigations with 
extended-release exenatide are under way, currently target-
ing adult patients with established T1DM.25
Liraglutide
Liraglutide, the second approved GLP-1 agonist, is a once-
daily preparation with a half-life of 11 to 15 hours.6 This 
results in continuous stimulation of the GLP-1 receptor, com-
pared with twice-daily exenatide, which only results in inter-
mittent exposure.6 Liraglutide is the most widely studied 
GLP-1 agonist in adult T1DM patients, as an add-on therapy 
to insulin. Six clinical trials were identified, and a summary 
of available clinical data is outlined in Table 2.8,26-30 Results 
of the 3 placebo-controlled trials are listed in terms of lira-
glutide plus insulin relative to insulin therapy alone 
(placebo).26-28 All studies involving liraglutide were done in 
adult patients. Despite the limited number of patients and 
varying study durations in the clinical trials, results are rela-
tively consistent across studies. Patients in the studies 
tended to be younger (<50 years old) in age, without any 
residual β-cell function, and many patients were on insulin 
pumps and underwent continuous glucose monitoring dur-
ing the study period. The studies contained a mix of patients 
who were above A1C goal and those who were at goal; 
however, most studies included patients who were not at 
glycemic targets. Similarly, the studies were a mix of nor-
mal-weight and overweight patients, although normal 
weight predominated.
In regard to glycemic control, studies consistently 
showed an approximate 0.2% to 0.5% A1C lowering when 
liraglutide was added on to insulin therapy. In trials with-
out a control group, this result was always statistically 
significant.8,29,30 Conversely, in placebo-controlled trials, 
there was no significant difference in A1C lowering.26-28 
Additionally, plasma glucose decreased by roughly 20 mg/
dL when liraglutide was added to insulin. This effect was 
not statistically significant when the studies contained a 
comparator group. The nonsignificant difference in glyce-
mic control in studies when compared with insulin alone 
can likely be explained by insulin regimens being titrated 
toward desired goals.
A similar effect was observed among the trials in regard 
to TDD of insulin. TDD of insulin was reported differently 
among studies, including international units (IU)/d, IU/
kg/d, or as a percentage reduction. In all trials, the reduction 
of TDD of insulin was statistically significant. The overall 
effect was approximately 4 to 5 IU/d, 0.1 to 0.2 IU/kg/d, or 
20%. Part of this observed reduction may be explained by 
patients’ weight loss during the study period. Overall, addi-
tion of liraglutide exhibited a modest, but significant, reduc-
tion of TDD of insulin in the studies identified.
Other effects reported include weight loss and GI ADRs. 
All 6 trials reported effects of liraglutide on body 
weight.8,26-30 Liraglutide produced a statistically significant 
reduction in body weight, averaging 2.3 to 6.8 kg over a 4- 
to 24-week period, respectively. This effect was seen 
regardless of baseline body weight or BMI of the study 
population; however, it was more pronounced in the trials 
that included overweight patients with T1DM.26,30 It appears 
that liraglutide produces a modest reduction in body weight, 
which may or may not be a desired effect depending on the 
patient’s baseline weight. GI ADRs were frequently reported 
in clinical trials. Nausea was the most common GI ADR, 
ranging from 11% to 100%.8,26-30 In studies with a control 
group, GI ADRs were more common in the liraglutide 
group, which may present a potential barrier in clinical 
practice. Liraglutide was initiated at 0.6 mg subcutaneously 
once daily and titrated up to 1.2 or 1.8 mg once daily in all 
trials to lessen the risk of GI ADRs. Incidence of hypogly-
cemia either did not differ or was observed significantly 
less often compared with insulin alone or compared with a 
time period prior to initiation of liraglutide.8,26-30 Drop-out 
rates as a result of ADRs were similar across all trials, and 
the difference was not statistically significant when com-
pared with placebo.26,27
A recently published, double-blinded, randomized, pla-
cebo-controlled trial, the Lira-1 study, recruited 100 par-
ticipants with uncontrolled T1DM (A1C > 8%) who were 
overweight (BMI > 25 kg/m2).26 This is the largest clinical 
trial of GLP-1 agonists in T1DM to date and warrants tar-
geted discussion. The primary outcome of A1C lowering 
at 24 weeks was nonsignificant, with an absolute reduc-
tion of 0.5% from baseline and an additional lowering of 
0.2% as compared with placebo (P = 0.18). Additionally, a 
decrease of TDD was not significant when adjusted for 
decrease in weight (P = 0.1162). Body weight, on the 
other hand, was significantly reduced by 6.8 kg as com-
pared with placebo at 24 weeks (P = 0.01). Patients in the 
liraglutide group reported significantly less perceived 
hypoglycemia episodes than those in the placebo group, 
though there was no difference in rates of hypoglycemia 
during the 6-day continuous glucose monitoring periods at 
0, 12, and 23 weeks.26
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Although the trials included a limited number of patients 
overall, the effects of liraglutide were seen consistently 
among studies. Liraglutide, when added to insulin, pro-
duces a modest reduction in A1C and reduces plasma glu-
cose by about 20 mg/dL. In addition, it reduces TDD of 
insulin and body weight. However, liraglutide may increase 
the incidence of GI ADRs. It may be beneficial as add-on 
therapy in patients with uncontrolled T1DM (above A1C 
goal) in whom weight reduction is desired (ie, overweight 
or obese patients). A randomized clinical trial to further 
investigate the use of liraglutide in overweight and obese 
patients treated with insulin pumps is currently ongoing.31
Comparison to Pramlintide
As discussed earlier, the only noninsulin agent currently 
approved for T1DM is pramlintide. Only 1 study has been 
published comparing pramlintide to a GLP-1 agonist, 
exenatide, in T1DM.21 This was a single-day, proof-of-con-
cept study. In comparison to insulin monotherapy, exena-
tide significantly reduced postprandial plasma glucose and 
glucagon secretion, whereas pramlintide did not. More 
patients in the exenatide group experienced nausea, with 1 
patient experiencing vomiting that was resolved by admin-
istration of ondansetron. Limitations to this study include 
small sample size (10 patients completed the trial) and lim-
ited duration. The authors did not reveal the frequency of 
hypoglycemia in either group.21
Discussion
The use of GLP-1 agonists has been studied in patients on 
aggressive insulin regimens in both newly diagnosed and 
established T1DM. Prospective trials are limited in number, 
and sample sizes are small in all studies. Additionally, 1 
study with liraglutide was only 4 weeks long, making it dif-
ficult to draw conclusions regarding A1C lowering based 
on this study alone.28 However, all other studies included in 
the analysis were 10 weeks or more in duration. As a whole, 
A1C lowering with GLP-1 agonists has been modest—up 
to a maximum of 0.6%.23 Though all trials showed a trend 
toward lower A1C with addition of a GLP-1 agonist, results 
were not statistically significant in trials with comparators 
for any agent.
Comparison of Available Agents
Liraglutide and exenatide have the most robust findings of 
available noninsulin therapies to support use in T1DM. 
Specifically, liraglutide has the most published data. A total 
of 221 total patients participated in liraglutide trials, though 
a single study contained 100 of those patients.26 Conversely, 
exenatide has the most data for long-term use in T1DM, 
with 1 trial extending for 18 months20; however, the total 
number of patients enrolled among studies was 49, signifi-
cantly less than for liraglutide. Dosing was inconsistent in 
exenatide studies, and more frequent dosing is required 
with the immediate-release formulation as compared with 
liraglutide. Results remained relatively consistent among 
trials, with a trend toward lower A1C seen with both lira-
glutide and exenatide. The additional benefit of weight loss 
may offset the lack of A1C lowering when compared with 
titrated insulin therapy. It is difficult to draw conclusions for 
albiglutide and dulaglutide because clinical trials utilizing 
these agents have yet to be published.
Considerations for Use
GLP-1 agonists have a low risk of hypoglycemia that is per-
haps decreased when compared with insulin monotherapy, 
likely because of a decrease in TDD of insulin. This is also 
a potential advantage over pramlintide, which has been 
associated with significantly more hypoglycemic episodes 
when compared with insulin monotherapy in clinical trials, 
although this could have been a result of a study protocol 
that did not allow for insulin adjustment.10 Weight-lowering 
effects could be advantageous in overweight or obese indi-
viduals and may contribute to the decrease in TDD of insu-
lin observed in trials. The Lira-1 trial, which included 
overweight or obese patients, demonstrated a weight loss of 
6.8 kg with liraglutide over insulin monotherapy at 24 
weeks, which was a 6.4% decrease from baseline body 
weight.26 Because patients experienced weight loss regard-
less of baseline weight in clinical trials, GLP-1 agonists 
should not be used in patients with low to normal BMIs.
Products vary widely in reconstitution procedures, stor-
age requirements, and dosing schedules. Adding a GLP-1 
agonist will increase the total number of injections, which is 
a potential barrier for compliance. For patients who are con-
cerned about additional injections, once-weekly dosing 
schedules could be advantageous; however, the longer-act-
ing GLP-1 agonists have not been prospectively studied in 
the setting of T1DM. Nonetheless, overall injection burden 
with GLP-1 agonists is less when compared with pramlint-
ide, which is administered prior to all major meals. Cost is 
a limiting factor and should be discussed with the patient 
prior to starting therapy. The average wholesale prices of 
exenatide and liraglutide for a 30-day supply are $694.32 
and $831.06, respectively.32,33
Controversial safety concerns have led to a boxed 
warning regarding the development of thyroid C-cell 
tumors, especially in patients with a personal or family 
history of specific thyroid tumors.34-36 There is addi-
tional concern for pancreatitis identified in postmarket-
ing reports.37,38 GI adverse effects—namely nausea, 
vomiting, and diarrhea—were nearly ubiquitous in clini-
cal trials.8,16,20,23,26-30 Titrating doses per manufacturer rec-
ommendations should reduce these effects, but some 
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patients may find the nausea to be intolerable. Other com-
mon adverse effects include injection site reactions and 
small, but significant, increases in heart rate.39
Special Populations
For patients with severe renal impairment (creatinine clear-
ance <30 mL/min), exenatide is not recommended. There 
have been postmarketing reports of acute kidney injury, 
sometimes requiring hemodialysis, with exenatide.40,41 Use 
of liraglutide in patients with moderate renal dysfunction 
and end-stage renal disease (ESRD) has been studied in 
patients with type 2 diabetes mellitus.42,43 Both groups were 
more susceptible to GI adverse effects than those with nor-
mal renal function.42,43 Dose titration of liraglutide should 
be done with caution in patients with renal dysfunction, and 
reduced treatment doses may be required.42,43 No studies 
investigating use of GLP-1 agonists have been completed in 
T1DM patients with renal dysfunction.
To date, only exenatide has been studied in pediatric 
patients with T1DM17; 8 patients 15 to 18 years old partici-
pated in a 3-part study. Participants had baseline insulin 
requirements captured over 5 hours following a standard 
carbohydrate load. For the remaining 2 parts, participants 
received single doses of exenatide 1.25 and 2.5 µg in addi-
tion to exogenous insulin therapy with an identical carbohy-
drate load. Each exenatide dose was separated by 3 weeks. 
During the 5-hour study period, both doses of exenatide 
demonstrated immediate glucose reduction and statistically 
significant decreases in postprandial hyperglycemia and 
glucose AUC. Because of the limited study duration, ques-
tions remain regarding the long-term safety and efficacy in 
pediatric patients.17
Future Directions
The impact of GLP-1 agonists on the long-term complica-
tions of T1DM, including cardiovascular events, has not 
been studied. Prospective trials for use in renal impairment 
and pediatric patients, as well as utilizing long-acting for-
mulations, are needed. Albiglutide, a long-acting, once-
weekly GLP-1 agonist, is currently under investigation in 
T1DM.44 Additionally, studies addressing cost-effective-
ness and quality of life would be beneficial in helping eluci-
date the role of these agents in therapy.
Conclusion
As a whole, GLP-1 agonists are safe and potentially effec-
tive as add-on therapy to insulin in select T1DM patient 
populations—namely, those who are overweight or obese 
and not at glycemic goals despite aggressive insulin therapy. 
GI ADRs are relatively common with these agents, and slow 
titration using manufacturer guidelines should be utilized to 
lessen risk of nausea. At the current time, liraglutide has the 
strongest evidence for use, as demonstrated by total number 
of patients studied and consistency of dosing and results in 
clinical trials, and would be the agent of choice for use in 
T1DM at this time. Further studies on long-term effects of 
GLP-1 agonists on A1C lowering and related complications 
of T1DM would be advantageous in directing further use of 
these agents outside of their weight-lowering and insulin-
sparing effects.
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